

RECEIVED
CENTRAL FAX CENTER

OCT 23 2007

Appl. No. 10/699,277
Docket No. 8473MR2L
Customer No. 27752


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A composition suitable for oral administration to an animal for the purpose of sequestering one or more lipophilic materials present in the gastrointestinal tract of the animal, wherein the composition comprises a non-digestible, non-absorbable, open-celled polymeric foam comprising a polymeric material; wherein said polymeric foam is a high internal phase emulsion foam.
2. (Original) The composition according to Claim 1 wherein the foam has a density of less than about 0.1 g/cc.
3. (Original) The composition according to Claim 2 wherein the foam comprises a component selected from the group consisting of celluloses, chitins, chitosans, natural sponges, synthetic sponges, polyvinyl acetate, polyvinyl alcohol, polyurethanes, polyacrylates, polymethacrylates, polystyrenics, polyolefins, copolymers thereof, and mixtures thereof.
4. (Canceled).
5. (Currently Amended) The composition according to Claim 4 1, wherein the HIPE foam is characterized by the following:
 - (a) a specific surface area per foam volume of at least about 0.01 m²/cc; and
 - (b) a glass transition temperature (T_g) from about -40°C to about 90°C.

Appl. No.10/699,277
 Docket No. 8473MR2L
 Customer No. 27752

6. (Original)The composition according to Claim 1 further comprising a lipase inhibitor.
7. (Canceled).
8. (Currently Amended) The composition according to Claim 7 6, wherein the lipase inhibitor is selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.
9. (Original)The composition according to Claim 8 wherein at least one of the lipase inhibitors is a compound having the structure:



wherein A is the group,




or $-(CH_2)_5-$.

- 10-22. (Canceled)
23. (Currently Amended) A kit comprising:
 - (a) a first composition suitable for oral administration comprising a non-digestible, non-absorbable, open-celled polymeric foam; and
 - (b) a second composition comprising a component selected from the group consisting of

Appl. No.10/699,277
 Docket No. 8473MR2L
 Customer No. 27752

vitamins, lipase inhibitors, laxatives, and combinations thereof.

24. (Original) The kit according to Claim 23 wherein the foam is a HIPE foam.
25. (Original) The kit according to Claim 23 wherein the second composition comprises a lipase inhibitor selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.
26. (Original) The kit according to Claim 25 wherein the lipase inhibitor is a compound having the structure:



wherein A is the group.



or $-(CH_2)_5-$.

27. (Currently Amended) A kit comprising:
- (a) a composition suitable for oral administration comprising a non-digestible, non-absorbable, open-celled polymeric foam; and
 - (b) information associated with the composition that use of the composition will provide one or more benefits selected from the group consisting of sequestration of lipophilic materials, treatment of gastrointestinal distress, treatment of fecal urgency, treatment of obesity, weight loss, weight control, treatment of hyperlipidemia, treatment of diarrhea, inhibition

Appl. No.10/699,277
Docket No. 8473MR2L
Customer No. 27752

of anal leakage, reduction of levels of toxic substances, treatment of Type II Diabetes, delay of onset of Type II Diabetes, prevention of Type II Diabetes, and combinations thereof.

28. (Original) The kit according to Claim 27 wherein the foam is a HIPE foam.